Business
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
Grant provides $1.2 million in non-dilutive funding for 2022 sepsis clinical trial expensesTo date, Enlivex has received a total of $7.8 million in
About this update from Enlivex Ltd.
[{"type":"text","content":"Grant provides $1.2 million in non-dilutive funding for 2022 sepsis clinical trial expensesTo date, Enlivex has received a total of $7.8 million in non-dilutive grants from the Israel Innovation Authority, excluding this new grant Nes Ziona, Israel, May 25, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that the Israel Innovation Authority (IIA) selected Enlivex’s ongoing sepsis clinical program to receive a thirdnon-dilutive grant of approximately $1.2 million for 2022. To date, Enlivex has received a total of approximately $7.8 million in non-dilutive grants from the IIA for clinical trials and product development, excluding this newly approved grant. The IIA is an independent, publicly funded agency charged with fostering the development of industrial research and development within the State of Israel. It provides non-dilutive grants in the form of reimbursement for actual expenses pre-approved by the IIA. The grants become repayable only through royalties from future sales of products developed with the support of the IIA, and the repayment, if any, is limited to the original grant amount plus interest. Enlivex is currently recruiting patients to its Phase IIb trial of AllocetraTM for the treatment of organ dysfunction associated with sepsis. ABOUT ALLOCETRA™ Enlivex is developing AllocetraTM as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents. ABOUT ENLIVEXEnlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostat...